Japan-based Asahi Kasei Corp. offered to acquire Calliditas Therapeutics AB (CALT) in a tender offer valued at $1.12 billion to accelerate its growth as a global healthcare company.
Asahi Kasei offered to buy Calliditas for 11.8 billion Swedish crowns (about $1.12 billion), offering 208 crowns per share (about $19.75) to the shareholders of Calliditas and 416 crowns (about $39.5) to the holders of American Depositary Shares of Calliditas. The offer represents a premium of 83% compared to the last trading price of Calliditas’ shares on Nasdaq Stockholm of 113.6 crowns.